相似文献
1
Medical management of lower urinary tract symptoms.
Rev Urol. 2009 Fall;11(Suppl 1):S19-25.
2
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Eur Urol. 2011 Oct;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29.
3
Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
Drugs Today (Barc). 2016 Sep;52(9):501-517. doi: 10.1358/dot.2016.52.9.2525739.
4
The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
J Sex Med. 2014 Jun;11(6):1539-45. doi: 10.1111/jsm.12499. Epub 2014 Mar 13.
5
Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Curr Opin Urol. 2014 Jan;24(1):21-8. doi: 10.1097/MOU.0000000000000007.
6
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25.
7
Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
World J Urol. 2019 Jan;37(1):143-153. doi: 10.1007/s00345-018-2370-z. Epub 2018 Jun 12.
8
Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
Curr Opin Urol. 2010 Jan;20(1):49-54. doi: 10.1097/MOU.0b013e328333ac68.
9
[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6.
10
Current role for combination therapy in male LUTS.
Arch Esp Urol. 2010 Jun;63(5):323-32.
引用本文的文献
1
Smooth muscle of the lower urinary tract: BK-RyR coupling in physiology and pathophysiology.
J Muscle Res Cell Motil. 2025 Sep 1. doi: 10.1007/s10974-025-09707-w.
2
Lower urinary tract symptoms (LUTS) and sleep quality: the mediating role of anxiety and depression in middle-aged and older adults from the ardakan cohort study on aging (ACSA).
BMC Urol. 2025 Jul 4;25(1):157. doi: 10.1186/s12894-025-01835-2.
3
A Rare Case of a Giant Prostatic Urethral Stone and Its Management.
Cureus. 2025 Apr 3;17(4):e81677. doi: 10.7759/cureus.81677. eCollection 2025 Apr.
4
The use of beta-sitosterol for the treatment of prostate cancer and benign prostatic hyperplasia.
Am J Clin Exp Urol. 2023 Dec 15;11(6):467-480. eCollection 2023.
5
Prophylactic A-Blockers for Radiotherapy-Induced Lower Urinary Tract Symptoms in Men with Prostate Cancer: A Phase III Randomized Trial.
Cancers (Basel). 2023 Jun 30;15(13):3444. doi: 10.3390/cancers15133444.
6
Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size.
Int Urol Nephrol. 2023 Jul;55(7):1649-1658. doi: 10.1007/s11255-023-03602-4. Epub 2023 May 6.
7
The impact of short term, long term and intermittent infection on male C57BL/6J mouse prostate histology and urinary physiology.
Am J Clin Exp Urol. 2023 Feb 25;11(1):59-68. eCollection 2023.
8
The IL-4/IL-13 signaling axis promotes prostatic fibrosis.
PLoS One. 2022 Oct 6;17(10):e0275064. doi: 10.1371/journal.pone.0275064. eCollection 2022.
9
Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.
J Urol. 2019 Dec;202(6):1240-1247. doi: 10.1097/JU.0000000000000385. Epub 2019 Jun 12.
10
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Cochrane Database Syst Rev. 2018 Nov 16;11(11):CD010060. doi: 10.1002/14651858.CD010060.pub2.
本文引用的文献
1
Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.
J Urol. 2009 Jun;181(6):2634-40. doi: 10.1016/j.juro.2009.02.034. Epub 2009 Apr 16.
2
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.
Int J Urol. 2008 Mar;15(3):193-9. doi: 10.1111/j.1442-2042.2007.01956.x.
3
Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Pharmacotherapy. 2008 Mar;28(3):356-65. doi: 10.1592/phco.28.3.356.
4
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
J Urol. 2007 Apr;177(4):1401-7. doi: 10.1016/j.juro.2006.11.037.
5
6
Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.
J Urol. 2007 Mar;177(3):1071-7. doi: 10.1016/j.juro.2006.10.055.
7
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Eur Urol. 2007 Jun;51(6):1717-23. doi: 10.1016/j.eururo.2007.01.033. Epub 2007 Jan 16.
8
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
JAMA. 2006 Nov 15;296(19):2319-28. doi: 10.1001/jama.296.19.2319.
9
The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis.
BJU Int. 2007 Jan;99(1):85-96. doi: 10.1111/j.1464-410X.2006.06574.x. Epub 2006 Oct 9.
10
Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
J Urol. 2006 Mar;175(3 Pt 1):999-1004; discussion 1004. doi: 10.1016/S0022-5347(05)00483-0.
Zotero 插件